EyePoint Pharmaceuticals (EYPT) Faces Major Setback as LUCIA Trial Misses Endpoint; Stock Under Pressure
· gurufocus.com
On October 19, 2026, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its LUCIA clinical trial failed to meet the primary endpoint for best-corrected visu
On October 19, 2026, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its LUCIA clinical trial failed to meet the primary endpoint for best-corrected visu...